Patients who are receiving conventional therapy according to the MOH protocol.

Patients will receive Liquorice cap and Boswellia Serrata gum in addition to conventional therapy

COVID-19

LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.
Dose:
One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour

Licorice extract

Faculty of Medicine, Assiut University

Complementary Intervention for COVID-19

Evaluation of The Potential Therapeutic Effects of Licorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 as a Complementary Medicine

Conversion of RT-PCR indicates positive for novel coronavirus RNA to negative

Decrease number of patients that require respiratory support , management in the Intensive Care Unit (ICU) and need Mechanical Ventilation Support with endotracheal intubation.

A pilot study for evaluation of the potential therapeutic effect of food supplement, licorice extract, and Boswellia Serrata gum

Adel Gomaa

Professor of medical pharmacology

Egyptian Biomedical Research Network

Study patients diagnosed with acute pouchitis after bowel surgery for ulcerative colitis will perform manuka honey enemas twice a day for 30 days.

Pouchitis

Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.

Manuka honey enema

Saint Paul's Hospital

To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis

To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis (Pilot Study)

PDAI score is a criterion for defining pouchitis. A PDAI score will be calculated from a proctoscopy assessment before treatment. Within two weeks after the treatment, another proctoscopy will be performed to determine the post-treatment PDAI score to see if there is a decrease in PDAI score for the study patients.

includes stool frequency (no different, 1-2 stools/day > postoperative usual, 3 or more stools/day > postoperative usual), rectal bleeding (none or rare or present daily), fecal urgency or abdominal cramps (none, occasional or usual), presence of fever (temperature >37.8° C), abdominal pain (no, occasional or usual) and readmission to hospital for any reason.

Dr. Carl J Brown

Head, Division of General Surgery, clinical assistant professor of surgery at University of British Columbia

Canadian Association of General Surgeons

All subjects in this arm (smokers (n=8) and non-smokers (n=8) will receive 81 mg aspirin at approximately 8 am followed by 1000 mg acetaminophen at approximately 10 am during one crossover period (see "Crossover period: Aspirin first" intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 1000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see "Crossover Period: Aspirin last" intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender.

All subjects in this arm (smokers (n=8) and non-smoking volunteers (n=8)) will receive 81 mg aspirin at approximately 8 am followed by 2000 mg acetaminophen at approximately 10 am during one crossover period (see "Crossover Period: Aspirin first" intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 2000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see "Crossover Period: Aspirin last" intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender.

Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. They will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM (see "Acetaminophen 1000 mg/d" intervention). Study assessments will be performed on day 1 and on day 6. This is not a crossover design. Just one treatment period.

Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. In one period of this crossover study acetaminophen (1000 mg p.o.) will be administered orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see "Crossover Period: Acetaminophen 4000 mg/d" intervention). The last dose will be administered on day four at 8 AM In the other crossover period, after a washout period of at least 14 days, the subjects will receive ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see "Crossover Period: Ibuprofen 800 mg/d" intervention). The last dose will be administered on day four at 8 AM Study assessments will be performed on day 1 and day 4 of each crossover period. The occurrence of the two crossover periods will be randomized by order.

All subjects in this arm (smokers (n=8) and non-smokers (n=8) will receive 81 mg aspirin at approximately 8 am followed by 1000 mg acetaminophen at approximately 10 am during one treatment phase (see "Aspirin first" intervention). During the other treatment phase, beginning after a 2 week washout, the order will be reversed and the subjects will receive 1000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see "Aspirin last" intervention). The occurrence of the two study phases (interventions) will be randomized by order. Smokers and non-smokers will be matched for age and gender.
Aspirin first: Subjects will receive 81 mg aspirin at approximately 8 am followed by 1000 or 2000 mg acetaminophen at approximately 10 am during this intervention phase.
Aspirin last: Subjects will receive 1000 or 2000 mg acetaminophen at approximately 8am followed by 81 mg aspirin at approximately 10 am during this intervention phase.

Phase 1a: Acetaminophen 1000mg / Aspirin

All subjects in this arm (smokers (n=8) and non-smoking volunteers (n=8)) will receive 81 mg aspirin at approximately 8 am followed by 2000 mg acetaminophen at approximately 10 am during one treatment phase (see "Aspirin first" intervention). During the other treatment phase, beginning after a 2 week washout, the order will be reversed and the subjects will receive 2000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see "Aspirin last" intervention). The occurrence of the two study phases (interventions) will be randomized by order. Smokers and non-smokers will be matched for age and gender.
Aspirin first: Subjects will receive 81 mg aspirin at approximately 8 am followed by 1000 or 2000 mg acetaminophen at approximately 10 am during this intervention phase.
Aspirin last: Subjects will receive 1000 or 2000 mg acetaminophen at approximately 8am followed by 81 mg aspirin at approximately 10 am during this intervention phase.

Phase 1a: Acetaminophen 2000mg / Aspirin

Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. They will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM (see "Acetaminophen 1000 mg/d" intervention). Study assessments will be performed on day 1 and on day 6.
Acetaminophen 1000 mg/d: They will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM.

Phase 1b: Acetaminophen 1000 mg Alone

Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. In one treatment period of this cross-over study acetaminophen (1000 mg p.o.) will be administered orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see "Acetaminophen 4000 mg/d" intervention). The last dose will be administered on day four at 8 AM In the other treatment period, after a washout period of at least 14 days, the subjects will receive ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see "Ibuprofen 800 mg/d" intervention). The last dose will be administered on day four at 8 AM.
Acetaminophen 4000 mg/d: Acetaminophen (1000 mg p.o.) orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
Ibuprofen 800 mg/d: Ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.

Phase 2: Acetaminophen vs. Ibuprofen

Total

Sex: Female, Male

Region of Enrollment

Thromboxan B2 is a stable metabolite of thromboxane A2. Thromboxane B2 formation during clotting of whole blood (37 degrees Celsius, 1 hour) is reflective of the capacity of platelets to form thromboxane A2. Serum Thromboxane B2 was measured by radio-immuno assay. The quantity of interest was percent change from start (8:00 am on day 1) to finish (8:00 am on last day) of each crossover period in serum thromboxane B2. This was calculated as: 100%*(value at start of period minus value at end of period)/value at start of period.

81 mg aspirin at 8 am followed by 1000 mg acetaminophen at 10 am.

Phase 1a: Acetaminophen 1000 mg / Aspirin First

1000 mg acetaminophen at 8am followed by 81 mg aspirin at 10 am.

Phase 1a: Acetaminophen 1000 mg / Aspirin Last

81 mg aspirin at 8 am followed by 2000 mg acetaminophen at 10 am.

Phase 1a: Acetaminophen 2000 mg / Aspirin First

2000 mg acetaminophen at 8am followed by 81 mg aspirin at 10 am.

Phase 1a: Acetaminophen 2000 mg / Aspirin Last

Phase 1b: Acetaminophen 1000 mg/d

Acetaminophen (1000 mg p.o.) orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. Last dose on day four at 8 AM.

Phase 2: Acetaminophen 4000 mg/d

Ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. Last dose on day four at 8 AM.

Phase 2: Ibuprofen 800 mg/d

Percent Change in Serum Thromboxane B2

Platelet aggregation was induced by 500 micro molar arachidonic acid using a Chronolog aggregometer. The quantity of interest was percent change from start (8:00 am on day 1) to finish (8:00 am on last day) of each crossover period in platelet aggregation. This was calculated as: 100%*(value at start of period minus value at end of period)/value at start of period.

Percent Change in Arachidonic Acid Induced Platelet Aggregation

All subjects in this arm of the study termed "Phase 1a" (smokers (n=8) and non-smokers (n=8) will receive 81 mg aspirin at 8 am followed by 1000 mg acetaminophen at 10 am each day, for six days during the first crossover period ("Aspirin first"). During the second crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 1000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am each day, for six days ("Aspirin last"). The occurrence of the two crossover periods (interventions) will be randomized by order. Smokers and non-smokers will be matched for age and gender.

Phase 1a: Aspirin 81 mg / Acetaminophen 1000 mg Sequence 1

All subjects in this arm of the study termed "Phase 1a" (smokers (n=8) and non-smokers (n=8) will receive 1000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am each day, for six days during the first crossover period ("Aspirin last"). During the second crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 81 mg aspirin at 8 am followed by 1000 mg acetaminophen at 10 am each day, for six days ("Aspirin first"). The occurrence of the two crossover periods (interventions) will be randomized by order. Smokers and non-smokers will be matched for age and gender.

Phase 1a: Aspirin 81 mg / Acetaminophen 1000 mg Sequence 2

All subjects in this arm of the study termed "Phase 1a" (smokers (n=8) and non-smokers (n=8) will receive 81 mg aspirin at 8 am followed by 2000 mg acetaminophen at 10 am each day, for six days during the first crossover period ("Aspirin first"). During the second crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 2000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am each day, for six days ("Aspirin last"). The occurrence of the two crossover periods (interventions) will be randomized by order. Smokers and non-smokers will be matched for age and gender.

Phase 1a: Aspirin 81 mg / Acetaminophen 2000 mg Sequence 1

All subjects in this arm of the study termed "Phase 1a" (smokers (n=8) and non-smokers (n=8) will receive 2000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am each day, for six days during the first crossover period ("Aspirin last"). During the second crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 81 mg aspirin at 8 am followed by 2000 mg acetaminophen at 10 am each day, for six days ("Aspirin first"). The occurrence of the two crossover periods (interventions) will be randomized by order. Smokers and non-smokers will be matched for age and gender.

Phase 1a: Aspirin 81 mg / Acetaminophen 2000 mg Sequence 2

Eight healthy, non-smoking subjects will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM. Study assessments will be performed on day 1 and on day 6.
Phase 1b is not a crossover design. Phase 1b will end after the first treatment period, which will be identical for all subjects.

Phase 1b: Acetaminophen 1000mg Alone: 4 Days

In the first period of this arm of the crossover study termed "Phase 2", healthy non-smoking subjects will be administered acetaminophen (1000 mg) orally at 8 AM, 2 PM, 8 PM and 2 AM (4000 mg/d) for 3 days. The last dose will be administered on day four at 8 AM In the other crossover period, after a washout period of at least 14 days, the subjects will receive ibuprofen (200 mg) orally at 8 AM, 2 PM, 8 PM and 2 AM (800 mg/d) for 3 days. The last dose will be administered on day four at 8 AM. The treatment periods will be randomized by order.

Phase 2: Acetaminophen 4000 mg/d / Ibuprofen 800 mg/d

In the first period of this arm of the crossover study termed "Phase 2", healthy non-smoking subjects will be administered ibuprofen (200 mg) orally at 8 AM, 2 PM, 8 PM and 2 AM (800 mg/d) for 3 days. The last dose will be administered on day four at 8 AM In the other crossover period, after a washout period of at least 14 days, the subjects will receive acetaminophen (1000 mg) orally at 8 AM, 2 PM, 8 PM and 2 AM (4000 mg/d) for 3 days. The last dose will be administered on day four at 8 AM. The treatment periods will be randomized by order.

Phase 2: Ibuprofen 800 mg/d / Acetaminophen 4000 mg/d

Crossover Period 1

Washout (>/= 14 Days)

Crossover Period 2

Tilo Grosser, MD

Myocardial Infarction

Arthritis

Crossover period Aspirin First: Subjects will receive 81 mg aspirin at approximately 8 am followed by acetaminophen at approximately 10 am.

Aspirin First

Crossover period Aspirin Last: Subjects will receive acetaminophen at approximately 8 am followed by 81 mg aspirin at approximately 10 am.

Aspirin Last

Subjects will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM.

Acetaminophen 1000 mg/d

Crossover period Acetaminophen 4000 mg/d: Acetaminophen (1000 mg p.o.) orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.

Acetaminophen 4000 mg/d

Crossover period Ibuprofen 800 mg/d: Ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.

Ibuprofen 800 mg/d

Institute for Translational Medicine and Therapeutics, University of Pennsylvania

phenolic/fiabhras

Complementary Intervention for COVID-19

To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis

Mechanisms of Action of Acetaminophen

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht